Lamivudine use in pregnant HBsAg-females effectively reduces maternal viremia.

Background And Study Aims: Mother-infant hepatitis B virus (HBV) transmission is the current leading cause of chronic infection. We aimed to assess the efficacy of lamivudine use in hepatitis B surface antigen (HBsAg)-positive pregnant women to decrease viral load and thus aid in the prevention of transmission.

Patients And Methods: A study of 73 mother-infant pairs.